Every Form 4 that Thermo Fisher Scientific Inc. (TMO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TMO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TMO filings page.
THERMO FISHER SCIENTIFIC INC. (TMO) reported that Chairman & CEO Marc N. Casper had 1,256.617 shares of common stock withheld or delivered on 2026-08-28 to satisfy exercise price or tax liability, in two code F transactions at $622.18 per share. The filing also lists indirect holdings of 11,300 shares by the Alison Casper 2020 Irrevocable Trust and 5,000 shares by the MNC 2020 Irrevocable Trust, for which Casper disclaims beneficial ownership except for any pecuniary interest. The Rule 10b5-1 trading-plan checkbox was not selected.
THERMO FISHER SCIENTIFIC INC. (TMO) reported insider activity by Sr. Vice President & CFO James Meyer on August 28, 2026. He had five code F transactions in common stock, delivering or withholding a total of 270.28 shares at $622.18 per share for payment of exercise price or tax liability. A separate entry reports indirect ownership of 58.47 shares held through the TMO 401(k) plan, including 0.10 shares acquired between August 21 and August 28, 2026.
THERMO FISHER SCIENTIFIC INC. (TMO) reported an insider transaction by Thomas B. Shropshire Jr., SVP and General Counsel. On 2026-08-28, 49.024 shares of common stock were disposed of at $622.18 per share to satisfy exercise price or tax liability by delivering or withholding shares, rather than through an open-market sale. After this transaction, Shropshire directly owned 6,008.5 shares of Thermo Fisher common stock.
THERMO FISHER SCIENTIFIC INC. (TMO) reported that Executive Vice President Michael D. Shafer had four Form 4 transactions on 2026-08-28. In total, 790.041 shares of common stock were disposed of at $622.18 per share through code F transactions, representing shares delivered or withheld to pay the exercise price or tax liability in connection with equity awards.
THERMO FISHER SCIENTIFIC INC. (TMO) reported that officer Joseph R. Holmes, VP & Chief Accounting Officer, had company stock withheld on August 28, 2026 to cover exercise price or tax liability. Four Form 4 transactions show a total of 49.899 shares of common stock disposed at a price of $622.18 per share. These are coded as dispositions for payment of obligations rather than open-market purchases or sales, and post-transaction holdings are not stated in this filing.
THERMO FISHER SCIENTIFIC INC. (TMO) insider Gianluca Pettiti, President & COO, reported an option exercise and related share sales. On August 31, 2026, he exercised 3,733 stock options at an exercise price of $309.63 per share, increasing his option holdings to 7,467 options. He acquired 3,733 common shares from the exercise and sold a total of 4,133 common shares at $614.38 per share pursuant to a Rule 10b5-1 trading plan adopted on June 2, 2026. On August 28, 2026, a total of 1,034.692 shares of common stock were delivered or withheld at $622.18 per share for payment of exercise price or tax liability.
THERMO FISHER SCIENTIFIC INC. (TMO) reported that officer Lisa P. Britt, Sr. VP and Chief HR Officer, had four code F transactions on 2026-08-28, in which a total of 393.569 shares of common stock were delivered or withheld to pay the exercise price or tax liability at $622.18 per share.
THERMO FISHER SCIENTIFIC INC. (TMO) reported that Chairman & CEO Marc N. Casper exercised a stock option for 275 shares of common stock at an exercise price of $309.63 per share and disposed of the derivative position, leaving 0 option shares outstanding from that grant. The resulting 275 common shares were then sold in multiple open-market transactions totaling 275 shares at weighted average prices between approximately $625.00 and $628.89 per share, all on August 24, 2026.
The transactions were effected under a Rule 10b5-1 trading plan adopted on April 27, 2026. In addition, indirect holdings are reported as 5,000 shares held by the MNC 2020 Irrevocable Trust and 11,300 shares held by the Alison Casper 2020 Irrevocable Trust, with the reporting person disclaiming beneficial ownership except to any pecuniary interest.
THERMO FISHER SCIENTIFIC INC. (TMO) reported that Sr. Vice President & CFO James Meyer had 30.945 shares of common stock withheld or delivered on August 22, 2026 to satisfy exercise price or tax liability at a reference price of $629.27 per share. After this, he held 5,830.038 shares of TMO common stock directly, which include 19.519 shares acquired under the issuer’s employee stock purchase plan, and 58.37 shares indirectly through the TMO 401(k) plan, including 8.34 shares accumulated between March 1 and August 21, 2026.
THERMO FISHER SCIENTIFIC INC. (TMO) reported insider transactions by Chairman & CEO Marc N. Casper involving option exercises and share sales. On August 20 and 21, 2026, he exercised stock options for a total of 20,000 shares of common stock at an exercise price of $309.63 per share. On the same dates, he sold an aggregate of 20,000 shares of common stock in multiple transactions at weighted average prices generally between the mid‑$620s and low‑$630s per share, as described in the sale footnotes. The transactions were effected pursuant to a Rule 10b5‑1 trading plan adopted on April 27, 2026. Indirect holdings include 11,300 shares held by the Alison Casper 2020 Irrevocable Trust and 5,000 shares held by the MNC 2020 Irrevocable Trust, for which beneficial ownership is disclaimed except to the extent of any pecuniary interest.
THERMO FISHER SCIENTIFIC INC. (TMO) reported an insider equity transaction by Lisa P. Britt, Sr. VP and Chief HR Officer. On August 19, 2026, she exercised stock options for 11,440 shares of common stock at an exercise price of $418.32 per share and then sold 11,440 shares of common stock at a weighted average price of $613.12 per share, with individual sale prices ranging from $613.09 to $613.49.
Thermo Fisher Scientific Executive Vice President Michael D. Shafer reported option exercises and stock sales. On August 11, 2026, he exercised options for 25,500 shares of common stock at strike prices of $309.63 and $418.32 per share and acquired the same number of shares. He then sold 25,500 shares at $600.00 per share pursuant to a Rule 10b5-1 trading plan adopted on December 11, 2025. A footnote states his holdings include an additional 44.079 shares acquired under the employee stock purchase plan on May 15, 2026, and the options exercised had vested in four equal installments from February 25, 2021 through February 25, 2024.
THERMO FISHER SCIENTIFIC INC. executive Joseph R. Holmes, VP & Chief Accounting Officer, exercised stock options for 420 shares of common stock at an exercise price of $309.63 per share on August 7, 2026, and sold 420 shares at $584.81 per share the same day. Following the option exercise, he reported 140 stock options remaining from this grant, which expires on February 25, 2027.
THERMO FISHER SCIENTIFIC INC. Chairman & CEO Marc N. Casper reported exercising options for 275 shares of common stock at an exercise price of $309.63 per share, leaving 20,275 option shares outstanding. On the same date, entities associated with him sold 4,883 common shares, through multiple open-market transactions at weighted average prices generally between $577.37 and $593.36 per share, including sales by Floral Park Associates, Inc. The trades were effected under a Rule 10b5-1 trading plan adopted on April 27, 2026. Indirect holdings include 5,000 shares held by MNC 2020 Irrevocable Trust and 11,300 shares held by Alison Casper 2020 Irrevocable Trust, for which Casper disclaims beneficial ownership except to any pecuniary interest.
Thermo Fisher Scientific executive Lisa P. Britt, Sr. VP and Chief HR Officer, exercised stock options for 5850.0000 shares of common stock at an exercise price of $309.6300 per share on August 6, 2026, then sold 5850.0000 shares at $580.0000 per share the same day. The option, covering 5850.0000 shares and originally expiring on 2027-02-25, had vested in four equal installments from 2021 through 2024 and is now fully exercised with no remaining derivative position.
Thermo Fisher Scientific Chairman & CEO Marc N. Casper exercised stock options for 10,000 shares of common stock at an exercise price of $309.63 per share on August 6, 2026, then, under a Rule 10b5-1 trading plan adopted April 27, 2026, sold an aggregate 15,000 common shares in multiple transactions at weighted-average prices generally between the low $570s and high $570s, both directly and indirectly through Floral Park Associates, Inc. The exercised option, which vested in four equal installments from 2021–2024, expires on February 25, 2027, and 20,550 options remain outstanding afterward.
Thermo Fisher Scientific Chairman & CEO Marc N. Casper exercised 10,000 stock options at $309.63 per share on August 5, 2026, acquiring an equal number of common shares, and then, together with an affiliated entity, sold 15,000 shares at weighted‑average prices between $565.86 and $577.63 under a Rule 10b5‑1 trading plan adopted April 27, 2026. The exercised option grant now shows 30,550 options remaining, expiring February 25, 2027.
Thermo Fisher Scientific Inc. President & COO Gianluca Pettiti sold 400 shares of Common Stock on July 27, 2026 at $565.00 per share in an open-market or private transaction. The sale was effected under a Rule 10b5-1 trading plan adopted on September 12, 2025, and left him with 24,650.832 directly owned shares.
SPERLING SCOTT M reported acquisition or exercise transactions in this Form 4 filing.
Thermo Fisher Scientific director Scott M. Sperling received a routine equity-based compensation award. He was granted 82.84 Phantom Stock Units on June 27, 2026 under the company’s Deferred Compensation Plan for Directors.
These units are credited at a price of $513.03 per unit and are convertible into Common Stock on a 1-for-1 basis. Following this grant, Sperling holds a total of 17,674.64 Phantom Stock Units. The stock units are scheduled to be distributed in shares of Common Stock when his board service ends for any reason or upon a change of control.
Keith R. Alexandra reported acquisition or exercise transactions in this Form 4 filing.
Thermo Fisher Scientific director Keith R. Alexandra received a grant of 60.910 Phantom Stock Units on June 27, 2026 under the company’s Deferred Compensation Plan for Directors. These units are credited at $513.03 per unit and are convertible into Common Stock on a 1-for-1 basis.
Following this grant, Alexandra holds a total of 1,331.350 Phantom Stock Units, which will be distributed in shares of Common Stock after his board service ends or upon a change of control.
WEISLER DION J reported acquisition or exercise transactions in this Form 4 filing.
Thermo Fisher Scientific director Dion J. Weisler received a grant of 73.1 Phantom Stock Units. These derivative units are convertible into Common Stock on a 1-for-1 basis and were credited at a price of $513.03 per unit under the company’s Deferred Compensation Plan for Directors.
Following this award, Weisler holds a total of 2,790.99 Phantom Stock Units. According to the plan, the related shares of Common Stock are distributable after director service ends for any reason or upon a change of control.
THERMO FISHER SCIENTIFIC INC. director Karen S. Lynch received a grant of 60.910 Phantom Stock Units on Common Stock. These units were credited to her deferred compensation account at a price of $513.03 per unit under the Deferred Compensation Plan for Directors.
The Phantom Stock Units convert into Common Stock on a 1-for-1 basis and are distributable as stock when her board service ends for any reason or upon a change of control. Following this grant, her account reflects 352.400 stock units.
THERMO FISHER SCIENTIFIC INC. director Jennifer M. Johnson reported a compensation-related award of phantom stock units. She acquired 60.910 Phantom Stock Units on June 27, 2026, each convertible into one share of Common Stock, bringing her total phantom stock holdings to 722.220 units.
These units were credited at a price of $513.03 per unit under the company’s Deferred Compensation Plan for Directors, where quarterly retainers are deferred into Common Stock units based on the closing stock price at quarter end. The units are distributable as stock after she ceases serving as a director for any reason or upon a change of control.
Thermo Fisher Scientific director Dion J. Weisler received a grant of 499 shares of Common Stock, increasing his direct holdings. On the same date, 80.287 shares were withheld at $451.79 per share to satisfy tax obligations related to this award, leaving him with 5,446.384 directly held shares.
Thermo Fisher Scientific director Scott M. Sperling received an award of 499 shares of Common Stock at no cost, classified as a grant or other acquisition. After this compensation grant, he directly holds 69,479 shares of Thermo Fisher Scientific common stock.
Spar Debora L reported acquisition or exercise transactions in this Form 4 filing.
THERMO FISHER SCIENTIFIC INC. director Debora L. Spar reported receiving a grant of 499 shares of Common Stock on May 20, 2026. The award carried a stated price of $0.00 per share, indicating compensation rather than an open-market purchase. After this grant, she directly holds 2,610 shares of Thermo Fisher stock, reflecting a routine equity compensation transaction rather than a market trade.
Lynch Karen S reported acquisition or exercise transactions in this Form 4 filing.
THERMO FISHER SCIENTIFIC INC. director Karen S. Lynch reported a stock award of 499 shares of common stock on May 20, 2026, recorded at $0.0000 per share. After this grant, she directly owns 1,159 common shares. The filing also reports 76 additional common shares held indirectly through a living trust.
Keith R. Alexandra reported acquisition or exercise transactions in this Form 4 filing.
Thermo Fisher Scientific director Keith R. Alexandra received a stock grant of 499 shares of Common Stock as compensation, not an open-market purchase. The shares were awarded at a stated price of $0.00 per share, increasing his directly held position to 2,602 shares following the transaction.
JOHNSON JENNIFER M reported acquisition or exercise transactions in this Form 4 filing.
Thermo Fisher Scientific director Jennifer M. Johnson reported receiving a grant of 499 shares of Common Stock on May 20, 2026. The award was recorded at a price of $0.00 per share, indicating it was part of her director compensation rather than an open-market purchase. After this grant, she directly holds a total of 1,403 shares of Thermo Fisher Scientific common stock.
Jacks Tyler reported acquisition or exercise transactions in this Form 4 filing.
THERMO FISHER SCIENTIFIC INC. director Tyler Jacks received a grant of 499 shares of common stock on May 20, 2026. The award was granted at no cash cost per share and increased his directly held position to 9,462 shares. This is a routine compensation-related equity grant rather than an open-market purchase.
HARRIS C MARTIN reported acquisition or exercise transactions in this Form 4 filing.
Thermo Fisher Scientific director Harris C. Martin received a grant of 499 shares of Common Stock on May 20, 2026 at no cash cost. This compensation-related award increased his direct holdings to 9,532 shares. The filing does not report any open-market buying or selling.
THERMO FISHER SCIENTIFIC INC. director Ruby R. Chandy received a grant of 499 shares of Common Stock on May 20, 2026 at no cost as compensation. Following this award, Chandy directly holds 3,463 shares, indicating a routine, non-market acquisition rather than an open-market purchase or sale.
Thermo Fisher Scientific director Nelson Chai received a stock grant of 499 shares of Common Stock. The shares were acquired at a stated price of $0.00 per share, indicating a compensation-related award rather than an open-market purchase. Following this grant, Chai directly holds 15,316 shares of Thermo Fisher Scientific Common Stock.
Thermo Fisher Scientific President & COO Gianluca Pettiti sold 400 shares of Common Stock in an open-market transaction. The sale occurred on April 27, 2026 at a price of $462.66 per share. The transaction was made under a Rule 10b5-1 trading plan adopted on September 12, 2025. After this sale, Pettiti continues to hold 25,050.832 shares of Thermo Fisher Scientific Common Stock directly.
SPERLING SCOTT M reported acquisition or exercise transactions in this Form 4 filing.
Thermo Fisher Scientific director Scott M. Sperling received a grant of 89.780 Phantom Stock Units, each convertible into one share of Common Stock. The units were credited on the director’s deferred compensation account at a price of $473.36 per unit under the company’s Deferred Compensation Plan for Directors.
Following this grant, Sperling now holds a total of 17,591.800 stock units in this account. These units are scheduled to be distributed in shares of Common Stock when his board service ends for any reason or if there is a change of control.
Keith R. Alexandra reported acquisition or exercise transactions in this Form 4 filing.
Thermo Fisher Scientific director Keith R. Alexandra received a grant of 66.02 Phantom Stock Units tied to common shares. These units were credited on March 28, 2026 at a reference price of $473.36 per unit under the company’s Deferred Compensation Plan for Directors. Each unit is convertible into one share of common stock and is distributable as stock when his board service ends or upon a change of control. Following this grant, Alexandra holds a total of 1,270.44 Phantom Stock Units directly.
Lynch Karen S reported acquisition or exercise transactions in this Form 4 filing.
Thermo Fisher Scientific director Karen S. Lynch received 66.02 Phantom Stock Units tied to common stock as deferred compensation. These units are credited under the company’s Deferred Compensation Plan for Directors at $473.36 per unit and are convertible into common stock on a 1-for-1 basis.
Following this grant, Lynch holds a total of 291.49 phantom units. The units are scheduled to be distributed in stock after her board service ends for any reason or upon a change of control, aligning compensation with long-term shareholder value.
JOHNSON JENNIFER M reported acquisition or exercise transactions in this Form 4 filing.
THERMO FISHER SCIENTIFIC INC. director Jennifer M. Johnson received a grant of 66.0200 Phantom Stock Units on March 28, 2026. These units are convertible into Common Stock on a 1-for-1 basis and were credited at $473.36 per unit under the Deferred Compensation Plan for Directors.
Following this grant, Johnson holds a total of 661.3100 Phantom Stock Units. Directors’ retainers are deferred quarterly as Common Stock units based on the closing stock price at quarter end, with shares distributed as stock after director service ends or upon a change of control.
WEISLER DION J reported acquisition or exercise transactions in this Form 4 filing.
Thermo Fisher Scientific director Dion J. Weisler received a grant of 79.2200 Phantom Stock Units on March 28, 2026, as a deferred director retainer. These units are credited under the company’s Deferred Compensation Plan for Directors at a price of $473.36 per unit and are convertible into Common Stock on a 1-for-1 basis. Following this award, Weisler holds a total of 2,717.8900 phantom stock units, which will be distributable as company stock when his board service ends or if there is a change of control.
Thermo Fisher Scientific Executive Vice President Michael D. Shafer sold 1,607 shares of common stock in an open-market transaction. The sale occurred at a price of $499.40 per share, and followed a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025.
After this transaction, Shafer directly holds 20,949.9546 Thermo Fisher Scientific shares. Because the trade was executed under a Rule 10b5-1 plan, its timing reflects a preset schedule rather than a discretionary market-timing decision.
Thermo Fisher Scientific Chairman & CEO Marc N. Casper exercised stock options for 4,000 shares of common stock and reported related trades in Thermo Fisher Scientific Inc. stock. The option exercise, at an exercise price of $0.00 per share, converted into 4,000 shares of common stock.
On the same date, he sold 4,000 shares of common stock in a series of open-market transactions at prices ranging from $503.66 to $519.74, pursuant to a Rule 10b5-1 trading plan adopted on November 11, 2025. Following these transactions, he directly held 125,360.358 shares of common stock.
Additional shares are held indirectly by the Alison Casper 2020 Irrevocable Trust (11,300 shares), Floral Park Associates, Inc. (14,608 shares) and the MNC 2020 Irrevocable Trust (5,000 shares, all as of the reported date), with Casper disclaiming beneficial ownership of these indirect holdings except to the extent of any pecuniary interest.
Thermo Fisher Scientific Inc. Chairman & CEO Marc N. Casper reported option exercises and related share sales in company stock. On March 3 and 4, 2026, he exercised stock options for a total of 10,000 shares of Common Stock at a reported exercise price of $309.63 per share in multiple transactions coded as derivative exercises.
Over the same two days, Casper sold 10,000 shares of Common Stock in a series of open-market transactions, with prices reported around $495.29–$517.05 per share as weighted-average prices across multiple trades. The transactions were effected under a Rule 10b5-1 trading plan adopted on November 11, 2025. Following these transactions, he directly held 123,925.358 shares of Common Stock and 44,550 stock options. Additional shares are held indirectly through the Alison Casper 2020 Irrevocable Trust, the MNC 2020 Irrevocable Trust, and Floral Park Associates, Inc., for which he disclaims beneficial ownership except for any pecuniary interest.
Thermo Fisher Scientific Chairman & CEO Marc N. Casper reported two tax-withholding dispositions of common stock on February 28, 2026. He delivered 3,473.759 shares and 1,211.168 shares at $521.11 per share to cover tax liabilities, rather than executing open-market sales. Following these dispositions, he directly held 123,925.358 common shares. Additional common shares are held indirectly by the Alison Casper 2020 Irrevocable Trust, the MNC 2020 Irrevocable Trust, and Floral Park Associates, Inc., for which he disclaims beneficial ownership except to any pecuniary interest.
Thermo Fisher Scientific senior vice president and chief HR officer Lisa P. Britt reported two tax-withholding share dispositions. She transferred 262.6700 and 85.4090 shares of common stock at $521.1100 per share to cover tax liabilities. After these transactions, she directly owned 14,784.1480 common shares.
Thermo Fisher Scientific executive Joseph R. Holmes, VP & Chief Accounting Officer, reported several small dispositions of common stock on February 28, 2026. The transactions used code F, meaning shares were withheld to cover tax liabilities rather than sold in open-market trades. Blocks of stock were withheld at $521.11 per share, including 55.475 and 44.459 shares. After these tax-withholding dispositions, Holmes directly held about 2,966.3555 shares of Thermo Fisher common stock.
Thermo Fisher Scientific Executive Vice President Michel Lagarde reported two tax-withholding dispositions of common stock. On February 28, 2026, he delivered 836.8800 shares and 359.7250 shares of Thermo Fisher common stock at $521.1100 per share to cover tax obligations.
Thermo Fisher Scientific President & COO Gianluca Pettiti reported two tax-withholding dispositions of common stock under a Form 4. On February 28, 2026, he surrendered 741.7100 and 331.6810 shares at $521.11 per share to cover tax obligations, and directly owned 25,450.8320 shares afterward.
Thermo Fisher Scientific executive Stephen Williamson reported tax-related share dispositions. On February 28, 2026, he used two blocks of Common Stock, totaling 921.793 shares (674.724 and 247.069 shares), to satisfy tax obligations at a price of $521.11 per share, classified as tax-withholding dispositions rather than open-market sales.
After these transactions, Williamson held 32,499.4000 shares of Common Stock directly. He also reported 12,674.0000 shares held indirectly "By SLAT," with a footnote stating he disclaims beneficial ownership of indirectly owned securities except to the extent of any pecuniary interest.
Thermo Fisher Scientific Executive Vice President Michael D. Shafer reported three Form 4 transactions on common stock. He disposed of approximately 816 shares through tax-withholding dispositions at a reported price of $521.11 per share to satisfy tax obligations. After these transactions, he directly owns about 22,557 shares of Thermo Fisher Scientific common stock.
Thermo Fisher Scientific Executive Vice President Frederick M. Lowery reported several Form 4 transactions in common stock dated February 28, 2026. He disposed of shares through tax-withholding transactions at $521.11 per share, a method used to cover tax liabilities on equity awards rather than open-market selling. Following these dispositions, he directly held 15,308.3954 shares of common stock. The filing also shows indirect holdings of common stock through a 401(k) plan and a limited liability company. A footnote states he acquired 0.037 shares under the 401(k) plan between February 26 and February 28, 2026, and that he disclaims beneficial ownership of indirectly held securities except for any pecuniary interest.